Pathophysiology and management of multivalvular disease

Authors: Unger, Philippe; Clavel, Marie-Annick; Lindman, Brian R.; Mathieu, PatrickPibarot, Philippe
Abstract: Abstract | Multivalvular disease (MVD) is common among patients with valvular disease, and has a complex pathophysiology dependent on the specific combination of valve lesions. Diagnosis is challenging because several echocardiographic methods commonly used for the assessment of stenosis or regurgitation have been validated only in patients with single-valve disease. Decisions about the timing and type of treatment should be made by a multidisciplinary heart valve team, on a case-by-case basis. Several factors should be considered, including the severity and consequences of the MVD, the patient’s life expectancy and comorbidities, the surgical risk associated with combined valve procedures, the long-term risk of morbidity and mortality associated with multiple valve prostheses, and the likelihood and risk of reoperation. The introduction of transcatheter valve therapies into clinical practice has provided new treatment options for patients with MVD, and decision-making algorithms on how to combine surgical and percutaneous treatment options are evolving rapidly. In this Review, we discuss the pathophysiology, diagnosis, and treatment of MVD, focusing on the combinations of valve pathologies that are most often encountered in clinical practice
Document Type: Article de recherche
Issue Date: 28 April 2016
Open Access Date: Restricted access
Document version: VoR
Permalink: http://hdl.handle.net/20.500.11794/3268
This document was published in: Nature reviews. Cardiology, 1-12 (2016)
http:///dx.doi.org/10.1038/nrcardio.2016.57
Nature Publishing Group
Alternative version: 10.1038/nrcardio.2016.57
http://www.ncbi.nlm.nih.gov/pubmed/27121305
Collection:Articles publiés dans des revues avec comité de lecture

Files in this item:
SizeFormat 
Unger2016-15184E.pdf
4.82 MBAdobe PDF    Request a copy
All documents in CorpusUL are protected by Copyright Act of Canada.